We are delighted to have been granted the sole UK distribution rights for Caris Life Sciences’ MI Tumor Seek™, a comprehensive molecular profiling service used to help guide the management of advanced cancer.
Caris Life Sciences is a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionise healthcare. They provide a suite of market-leading tissue-based molecular profiling that precisely monitor DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Their MI Tumor Seek™ molecular profiling assay provides oncologists and surgeons with clinically important genomic information on key biomarkers and molecular signatures in oncology across all solid tumours.
The partnership will complement our existing portfolio of cancer risk testing, which will enable patients and oncologists to make informed decisions about their health and to take preventative measures that include regular screening programmes and improved lifestyle choices.
James Price, Chief Executive Officer at Everything Genetic, said: “We are delighted to partner with Caris Life Sciences for the sole UK distribution of MI Tumor Seek, their comprehensive molecular profiling service. The partnership will enable medical teams across the UK to access the precision diagnostic technologies for biomarker identification, and therefore to fully understand the biology of a tumour and to implement the best treatment strategy for their cancer patients. The partnership strengthens Everything Genetic’s position as the partner of choice for genetic testing in the UK.”
Andreas Tsukada, SVP and Head of International at Caris Life Sciences, said: “We are pleased to partner with Everything Genetic for the distribution of MI Tumor Seek in the UK, further supporting Caris’ goal of improving the lives of as many people as possible. This collaboration provides healthcare professionals the access to best-in-class diagnostic technologies that will enable them to make more precise and individualised treatment decisions for their cancer patients.”
The Caris team visited our HQ in Cheshire last week to finalise the partnership arrangements, and we look forward to working with them and playing a vital role in helping cancer care and treatment.
If you would like more information about the Caris MI Tumor Seek test, please contact us by email at: [email protected].